Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)

Aintzane Zabaleta, Esperanza Martín-Sánchez, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesus San-Miguel, David Martinez-Cuadron, Pau Montesinos, Bruno Paiva

Blood (2023) 142 (Supplement 1): 4178.

https://doi.org/10.1182/blood-2023-184797

Published: 2023

Journal Articles

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

Jiri Minarik, Ludek Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Martin Stork, Jan Straub, Vladimir Maisnar, Roman Hajek

Blood (2023) 142 (Supplement 1): 4733.

https://doi.org/10.1182/blood-2023-179299

Published: 2023

Journal Articles

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Roman Hajek, Henrik Sliwka, Martin Stork, Ivan Spicka, Tomas Jelinek, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Jan Soukup, Nolen Joy Perualila, Joris Diels, Michel van Speybroeck, Nichola Erler-Yates, João Mendes, Kai Strobel, Sébastien Wischlen, Maximilian Merz

Blood (2022) 140 (Supplement 1): 7200–7202.

https://doi.org/10.1182/blood-2022-159401

Published: 2022

Journal Articles

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Blood (2021) 138 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2021-148836

Published: 2021

Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tereza Popkova, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Tomas Jelinek, Petr Pavlicek, Marta Krejci, Jan Straub, Vladimir Maisnar, Tereza Dekojova, Tomas Pika, Jan Soukup, Lenka Capkova, Roman Hájek

Blood (2021) 138 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2021-153978

Published: 2021

Journal Articles

Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma

Ondrej Venglar, Tereza Sevcikova, Anjana Anilkumar Sithara, Veronika Kapustova, Jan Vrana, David Zihala, Ludmila Muronova, Lucie Huvarova, Lucie Broskevicova, Michal Simicek, Zdenek Koristek, Roman Hajek, Tomas Jelinek

Blood (2021) 138 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2021-150360

Published: 2021

Journal Articles

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Blood (2021) 138 (Supplement 1): 76.

https://doi.org/10.1182/blood-2021-146535

Published: 2021

Journal Articles

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Tomas Jelinek, Renata Bezděková, David Zihala, Tereza Sevcikova, Lenka Capkova, Petra Polackova, Martin Stork, Zdenka Knechtova, Ondrej Venglar, Artur Jurczyszyn, Jorge J. Castillo, Miroslav Penka, Jakub Radocha, Sabina Sevcikova, Ludek Pour, Lucie Rihova, Roman Hajek

Blood (2021) 138 (Supplement 1): 546.

https://doi.org/10.1182/blood-2021-151592

Published: 2021

Journal Articles

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Blood (2021) 138 (Supplement 1): 541.

https://doi.org/10.1182/blood-2021-150092

Published: 2021

Journal Articles

Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

Tomas Jelinek, David Zihala, Tereza Sevcikova, Veronika Kapustova, Hana Sahinbegovic, Anjana Anilkumar Sithara, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Jan Vrana, Vladimir Zidlik, Martin Havel, Zdenek Koristek, Juli R. Bago, Michal Simicek, Roman Hajek

Blood (2021) 138 (Supplement 1): 2680.

https://doi.org/10.1182/blood-2021-150876

Published: 2021

Journal Articles

Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling

David Zihala, Tereza Sevcikova, Michal Simicek, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Jan Vrana, Juli R. Bago, Roman Hajek, Giovanni Stracquadanio, Tomas Jelinek

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-142300

Published: 2020

Journal Articles

Prognostic Value of PET/CT Performed Day +100 Post Autologous Stem Cell Transplantation in Multiple Myeloma: Real-World Single Center Experience

Ludmila Muronova, Martin Havel, MD PhD, Tereza Popkova, Hana Plonkova, Roman Hajek, Tomas Jelinek

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142369

Published: 2020

Journal Articles

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Rosalinda Termini, Evangelos Terpos, MDPhD, Albert Pérez, MD, Tomas Jelinek, Nikoletta-Aikaterini Kokkali, Joan Bargay, MD, Fernando Solano Ramos, MD PhD, Sara Rodríguez, PhD, Cristina Pérez Ruiz, Catarina Maia, Antonio Sacco, RN, Marco Chiarini, MSc, Viviana Giustini, MSc, Jill Corre, PharmD, PhD, Francois Vergez, DVM, PhD, Marc S. Raab, MD, Niels Weinhold, PhD, Aitziber Lopez Lopez, Sonia Garate, Diego Alignani, PhD, Sarvide Sarai, Remco Loos, Antoni Garcia-Guiñon, MD, Maialen Sirvent, José Enrique de la Puerta, Rebeca Iglesias, Maria Casanova, MD, Maria Elena Cabezudo, Valentin Cabañas, MD, Enrique M. Ocio, MDPhD, Joaquin Martinez-Lopez, MD, Javier de la Rubia, Artur Paiva, Helena Vitoria, Catarina Geraldes, MD PhD, Roman Hajek, MD, Heinz Ludwig, MD, Hartmut Goldschmidt, MD, Herve Avet-Loiseau, Aldo M. Roccaro, MDPhD, Jesús F. San-Miguel, Bruno Paiva, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136251

Published: 2020

Journal Articles

Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients

Alexander Vdovin, Michal Durech, PhD, Tomas Jelinek, Tereza Sevcikova, PhD, Juli R. Bago, Matous Hrdinka, PhD, David Zihala, Renata Snaurova, Hana Sahinbegovic, Tereza Popkova, Ryszard Smolarczyk, PhD, Tomasz Cichon, PhD, Sebastian Giebel, MDPhD, Roman Hajek, MD PhD, Michal Simicek, PhD

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-140673

Published: 2020

Journal Articles

Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia

Tomas Jelinek, Jana Zuchnicka

Blood (2020) 135 (20): 1816.

https://doi.org/10.1182/blood.2020005020

Published: 2020

Journal Articles

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Alexander Vdovin, Tomas Jelinek, MD, Matous Hrdinka, PhD, Juli R. Bago, PhD, Tereza Sevcikova, Roman Hajek, Prof, MD PhD, Michal Simicek, PhD

Blood (2019) 134 (Supplement_1): 5526.

https://doi.org/10.1182/blood-2019-127930

Published: 2019

Journal Articles

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment

Tereza Popkova, MD, Katarina Hradska, MD, Jana Mihalyova, MD, Michaela Skorupova, Tomas Jelinek, MD, Juraj Duras, MD, Zdenek Koristek, MD PhD, Milan Navratil, MD, Katerina Benkova, MD, Hana Plonkova, MD, Jana Zuchnicka, MD, Jaromir Gumulec, MD, Roman Hajek, Prof, MD PhD

Blood (2019) 134 (Supplement_1): 4757.

https://doi.org/10.1182/blood-2019-127011

Published: 2019

Journal Articles

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

Blood (2019) 134 (Supplement_1): 3139.

https://doi.org/10.1182/blood-2019-128865

Published: 2019

Journal Articles

Whole Exome Sequencing of Residual Disease in Multiple Myeloma: Searching for Novel Therapeutic Targets

Martina Zátopková, MSc, Tereza Sevcikova, Zuzana Kufova, Katerina Growkova, Jana Filipova, Tomas Jelinek, Lucie Říhová, Renata Bezděková, MSc., Fedor Kryukov, Jana Smejkalová, Jiri Minarik, MD PhD, Vladimir Maisnar, MD, Martin Mistrik, MD PhD, Ludek Pour, MD, Alexandra Jungova, Michal Šimíček, Giovanni Stracquadanio, Roman Hajek

Blood (2018) 132 (Supplement 1): 3175.

https://doi.org/10.1182/blood-2018-99-112611

Published: 2018

NARROW

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling

Prognostic Value of PET/CT Performed Day +100 Post Autologous Stem Cell Transplantation in Multiple Myeloma: Real-World Single Center Experience

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients

Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

Whole Exome Sequencing of Residual Disease in Multiple Myeloma: Searching for Novel Therapeutic Targets

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only